MicroRNA expression in tumors and liquid biopsy samples from patients with pancreatic ductal adenocarcinoma: Identification of clinically relevant pathways

Background: Pancreatic carcinoma leads to 6.9% and 4% of all cancer-related deaths in the United States and Brazil, respectively. Pancreatic ductal adenocarcinoma (PDAC) comprises ~90% of pancreatic cancer cases and patients have a poor prognosis, mainly due to asymptomatic disease that leads to late diagnosis. Considering that diagnosis of disease in advanced stages is one of the main factors associated with mortality, the identification of circulating biomarkers in tumor and plasma (liquid biopsy) from patients is believed to be a clinically relevant strategy for early disease detection and treatment response monitoring. Objectives: We aimed to identify global microRNA (miRNA) expression changes in primary untreated tumors and plasma from patients diagnosed with PDAC. Deregulated miRNAs were mapped to miRNA-target genes, and PDAC tumorigenesis pathways were identified. Patients and Methods: 24 formalin-fixed, paraffin-embedded (FFPE) tumors and their paired normal pancreatic tissues were needle microdissected. In addition, 4 plasma samples from patients diagnosed with PDAC and 10 age-matched controls from individuals without disease were obtained. All samples were profiled using the TaqMan Array Human MicroRNA Cards (TLDA) (card A, v3.0) (Life Technologies). Data analysis was performed using ExpressionSuite Software v1.0.3. Computational miRNA target gene identification was performed using microRNA Data Integration Portal (mirDIP). Comprehensive pathway enrichment analysis based on identified miRNAs and target genes was performed using Pathway Data Integration Portal (pathDIP). Data were considered significant with Bonferroni corrected p-values. Results and Discussion: 63 miRNAs (33 over- and 30 underexpressed) were significantly deregulated (FC≥2 and p Conclusions: A 6-miRNA subset is commonly deregulated in plasma and tumors and associated with important signaling pathways in PDAC. miRNAs are likely valuable diagnostic and predictive biomarkers for patients with PDAC. Our data build on existing knowledge that liquid biopsy samples are a clinically useful and minimally invasive source for the development of molecular testing that should be translated to the clinical setting. Financial Support: TFF was awarded grant #2014/00367-4, Sao Paulo Research Foundation (FAPESP); TFF and NB a CAPES-DS Master9s Science fellowship. Computational analysis was supported in part by Canada Research Chair Program (#225404), Canada Foundation for Innovation (CFI #225404, #30865), Ontario Research Fund (#34876), IBM (IJ). Citation Format: Tainara F. Felix,* Natalia Bertoni,* Tomas Tokar, Maria A. M. Rodrigues, Rogerio A. Oliveira, Claudia N. Hasimoto, Juan C. Llanos, Igor Jurisica, Sandra A. Drigo, Robson F. Carvalho, Patricia P. Reis. MicroRNA expression in tumors and liquid biopsy samples from patients with pancreatic ductal adenocarcinoma: Identification of clinically relevant pathways [abstract]. In: Proceedings of the AACR International Conference held in cooperation with the Latin American Cooperative Oncology Group (LACOG) on Translational Cancer Medicine; May 4-6, 2017; Sao Paulo, Brazil. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(1_Suppl):Abstract nr B01.